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Focal and segmental glomerulosclerosis (FSGS) is a major
cause of end-stage kidney disease. Recent advances in
molecular genetics show that defects in the podocyte play a
major role in its pathogenesis and mutations in inverted
formin 2 (INF2) cause autosomal dominant FSGS. In order to
delineate the role of INF2 mutations in familial and sporadic
FSGS, we sought to identify variants in a large cohort of
patients with FSGS. A secondary objective was to define an
approach for genetic screening in families with autosomal
dominant disease. A total of 248 individuals were identified
with FSGS, of whom 31 had idiopathic disease. The remaining
patients clustered into 64 families encompassing 15 from
autosomal recessive and 49 from autosomal dominant
kindreds. There were missense mutations in 8 of the 49
families with autosomal dominant disease. Three of the
detected variants were novel and all mutations were
confined to exon 4 of INF2, a regulatory region responsible
for 90% of all changes reported in FSGS due to INF2
mutations. Thus, in our series, INF2 mutations were
responsible for 16% of all cases of autosomal dominant
FSGS, with these mutations clustered in exon 4. Hence,
screening for these mutations may represent a rapid,
non-invasive and cost-effective method for the diagnosis
of autosomal dominant FSGS.
Kidney International (2012) 81, 94–99; doi:10.1038/ki.2011.297;
published online 24 August 2011
KEYWORDS: familial nephropathy; focal segmental glomerulosclerosis;
genetic renal disease; human genetics; molecular genetics
Focal and segmental glomerulosclerosis (FSGS) is a common
cause of end-stage kidney disease (ESKD) worldwide. It is a
clinicopathological entity that is characterized by nephrotic
syndrome, rapid progression to ESKD, and pathological
changes of focal glomerulosclerosis on light microscopy, as
well as effacement of foot processes on electron microscopy.1
The etiology and pathogenesis of FSGS is not completely
known; however, recent advances in molecular genetics and
molecular biology provide insight into its pathogenesis. It is
now known that FSGS is a defect of the glomerular filtration
barrier (GFB). The GFB is made up of the podocyte and its
slit diaphragm, the glomerular basement membrane, and
specialized fenestrated endothelium. Disruption of the GFB
leads to loss of permselectivity and proteinuria. The podocyte
and its slit diaphragm have a central role in maintaining the
structural and functional integrity of the GFB. Evidence for
this is the development of nephrotic syndrome when genes
encoding the podocyte slit diaphragm and podocyte
cytoskeletal proteins are mutated.2–7
Mutations in inverted formin 2 (INF2) were recently
reported as a cause of autosomal dominant (AD) FSGS.8
Formin is one of the proteins that promote nucleation of
actin, a rate-limiting step in actin polymerization.9 INF2
is widely expressed in the kidney, especially in the podocytes
and tubules; it is also expressed in other organs such as
the liver, heart, placenta, and skeletal muscle.8 Transfection
experiments revealed that three of the reported mutations
(E184K, S186P, and R218Q) caused mislocalization of the
protein in undifferentiated cultured human podocytes,
suggesting that the mutations may cause FSGS by dysregula-
tion of the podocyte cytoskeleton.8 Most of the mutations
reported thus far in INF2 cluster in exon 4, a region of
the gene that encodes for the N-terminal regulatory region of
the protein.8–10 The prevalence of INF2 mutations in subjects
with familial and sporadic FSGS is unknown. In addition,
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the phenotype associated with it has not been fully
defined.
The main objective of this report is to determine the
frequency of INF2 mutations in a large cohort of patients
with sporadic and familial FSGS, and also describe the
phenotype associated with it.
RESULTS
Clinical data
We identified 217 individuals with FSGS from 64 families,
and 31 individuals with idiopathic FSGS. In all, 15 (15.8%)
families had two or more affected individuals in one
generation and they were classified as having presumed
autosomal recessive (AR) disease, and 49 (51.6%) had two or
more affected individuals in at least two generations and thus
were classified as having presumed AD disease. The racial
distribution, age at onset of disease, and age at ESKD in the
three groups are shown in Table 1. The subjects in the
idiopathic group had early-onset disease as compared with
the AR and AD data set (Kruskal–Wallis test; P¼ 0.005), but
there was no difference in age at onset of ESKD. There are
proportionately more African Americans in the idiopathic
group as compared with the AR and AD groups (38.7% vs.
20% vs. 28.6%); the difference was not statistically significant
(w2, P¼ 0.6). In all, 6 individuals in the idiopathic group are
known to have had kidney transplant, as well as 6 individuals
in the AR group and 22 individuals in the AD assemblage.
The recurrence rate of FSGS in renal allograft is higher in the
idiopathic group as compared with the AR and AD groups.
INF2 screening
We found variants in eight (8.4%) of the kindreds examined.
All of the variants were found in the AD group. All of the
variants caused nonconservative changes in highly conserved
amino acids and are clustered in exon 4 of INF2. Three of the
nonconservative changes reported in the present study have
not been previously reported. All of the newly identified
variants segregate with disease in the families. In addition,
seven individuals who were asymptomatic at the time of
ascertainment were also found to carry these changes. Table 2
shows the clinical characteristics of families with mutations in
INF2. None of the changes were identified in 192 control
chromosomes or in the 1000 Genomes catalog of human
genetic variations. The three new variants found in this study
are shown in Figure 1. All of the changes are highly conserved
in evolution down to zebrafish (Figure 1). In addition, all of
the changes had a Naive Bayes posterior probability of 499%
of being functionally damaging when modeled in silico11
(Table 3). The list of INF2 mutations reported so far in the
literature, including this study, is shown in Table 4. Supple-
mentary Table S1 online shows known and new INF2 variants
and single-nucleotide polymorphisms identified in this study.
Genotype/phenotype correlation
All eight families with INF2 mutations were of European
descent, including seven Caucasian families and a single
Hispanic family, also likely to be of European descent (Table 2).
In the subset of AD families without mutations in INF2, 51.2%
were Caucasian. There was no difference in age at onset, degree
Table 2 | Clinical phenotype of eight families with FSGS and mutations in INF2
Individual
number Race/country Mutation
Age onset
(years)
Symptomatic
individualsa Histology
Median age
at ESKD (years)
6502 C/USA Exon 4 608C4A A203Db 14–24 2/2 FSGS 42
6505 C/USA Exon 4 550G4C E184Qb 20–37 8/8 FSGS 33
6507 C/USA Exon 4 530G4A R177H 28–34 2/4 FSGS 36
6515 C/Canada Exon 4 653G4A R218Q 16–46 2/3 FSGS U
6518 C/New Zealand Exon 4 605A4G N202Db 19–24 2/2 FSGS U
6529 C/Belgium Exon 4 641G4A R214H 22–45 6/6 FSGS 45.5
6556 C/United Kingdom Exon 4 641G4A R214H 27–30 3/5 FSGS 40
6635 H/Uruguay Exon 4 641C4T R214C 20 1/3 FSGS U
Abbreviations: C, Caucasian; ESKD, end-stage kidney disease; FSGS, focal and segmental glomerulosclerosis; H, Hispanic; INF2, inverted formin 2; U, unknown.
aNumerator: number of individuals with FSGS, nephrotic syndrome, or chronic kidney disease in the family. Denominator: number of individuals with the mutation.
bNew mutations in this study.
Table 1 | Demographics of individuals and families with idiopathic and hereditary FSGS
Parameter Idiopathic (n=31) AR (n=15) AD (n=49)
Race (%)
White 51.6 73.3 59.2
African American 38.7 20.0 28.6
Others 9.7 6.7 12.2
Age at onset, median (range) years 9.0 (1.5–45) 21 (2.5–49) 24.5 (1–66)*
Median (range) proteinuria (g) 3.75 (3–20) 3 (2.4–20) 5 (1–20)
Age at ESKD, median (range) years 32 (8–45) 29.5 (6–50) 40 (8–63)
Transplant 6 7 22
Transplant recurrence 1/6 (16.7) 0/7 (0%) 2/22 (9.1%)
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; ESKD, end-stage kidney disease; FSGS, focal and segmental glomerulosclerosis.
*P=0.005.
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of proteinuria, age at ESKD between groups of AD subjects
with and without mutations in INF2. There was also no
significant difference in the rate of FSGS recurrence after renal
transplantation between these groups (1/3 vs. 1/19, respec-
tively). In all, 7 of 33 individuals carried an INF2 mutation but
were not symptomatic, indicating either reduced penetrance or
that they had yet to demonstrate signs of the disease.
Renal pathology in INF2 mutations and modeling of INF2
variants
Light microscopy of renal biopsies from two individuals with
R177H and A203D showed segmental sclerosis with adhe-
sions to Bowman’s capsule (Figure 2a–d). The biopsy from
the individual with the R177H variant showed collapsing
appearance in some glomeruli (Figure 2a and b). Mesangial
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Figure 1 |New inverted formin 2 (INF2) mutations in familial focal and segmental glomerulosclerosis (FSGS). (a) Protein domains of
INF2. (b) The three new mutations detected in families with FSGS. The new mutations (E184Q, N202D, and A203D) are all missense
mutations in exon 4 of the gene, which encode the diaphanous inhibitory domain (DID) of the protein. (c) Normal sequences.
(d) The three new mutations and the other four mutations identified in this cohort are well conserved in evolution down to the zebrafish.
*Denotes new mutations. DAD, diaphanous autoregulatory domain; FH, formin homology.
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staining for IgM and C3 was identified by immunofluores-
cence, and electron microscopy showed patchy epithelial foot
process effacement. Figure 2e and f shows three-dimensional
modeling of INF2 diaphanous inhibitory domain (DID)
based on the structure of mDia1. New variants identified in
this study mapped to the human INF2 homolog of critical
mouse mDia1 IQGAP1-interacting DID subdomain. In
addition, residues N202 and A203 model to the protein
surface next to I152, a residue identified as important for
direct interaction with diaphanous autoregulatory domain
(DAD).8,12,13
DISCUSSION
Familial cases of FSGS are responsible forB1% of all cases of
FSGS. However, previous studies of this subgroup have
illuminated our understanding of the pathogenesis of FSGS.
Mutations in INF2 were recently reported as a cause of
FSGS.8 In this study, we performed mutation analysis of INF2
in a large cohort of patients with familial and idiopathic
FSGS. We found mutations in INF2 in 16.3% of the families
with presumed AD FSGS and no mutations in individuals
with idiopathic disease or those with AR disease. We cannot
completely exclude a role for INF2 mutations in the etiology
of idiopathic and AR FSGS because of our limited sample
size. In addition, the difference in clinical characteristics
between idiopathic, AR, and AD FSGS should be interpreted
with caution, as this study is not population based; the
Table 3 | In silico prediction of effect of variants
Mutation Predicted effect
HumVar-
PolyPhen score
Exon4 608C4A, A203Da Probably damaging 0.997
Exon4 550G4C, E184Qa Probably damaging 0.995
Exon4 530G4A, R177H Probably damaging 0.997
Exon4 653G4A, R218Q Probably damaging 0.996
Exon4 605A4G, N202Da Probably damaging 0.992
Exon4 641G4A, R214H Probably damaging 0.997
Exon4 641C4T, R214C Probably damaging 0.997
aNew mutations in this study.
Table 4 | Scope of INF2 mutations in familial FSGS
Mutation Exon Ancestry
Number of
families
with change
Age of
onset
(years) Reference
A13T 2 European 1 21 8
L42P 2 European 1 11–13 8
L76P 2 European 1 27–44 13
R177H 4 European 3 19–34 13 and present
study
E184K 4 African
American
1 17–30 8
E184Q 4 European 1 20–37 Present study
S186P 4 European 2 12–67 8
Y193H 4 Middle
Eastern
1 24 13
L198R 4 European/
North
African
2 13–36 8 and 13
N202D 4 European 1 19–24 Present study
A203D 4 European 1 14–24 Present study
R214C 4 European/
Hispanic
3 5–44 13 and present
study
R214H 4 European 4 12–72 8 and present
study
R218Q 4 European 4 10–46 8, 13, and
present study
R218W 4 African
American
1 27–33 8
E220K 4 European/
Korean
3 7–30 8, 10, 13
Abbreviations: FSGS, focal and segmental glomerulosclerosis; INF2, inverted formin 2.
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Figure 2 |Renal biopsy in inverted formin 2 (INF2) mutation
and location of INF2 mutations in three-dimensional
modeling of INF2 diaphanous inhibitory domain (DID) based
on the structure of mDia1. Light microscopy of renal biopsies
from two individuals with R177H and A203D showed segmental
sclerosis with adhesions to Bowman’s capsule (a–d). The biopsy
from the individual with the R177H variant showed collapsing
appearance in some glomeruli (a, b). A model of human INF2
amino acids 1–330 was constructed using the Phyre threading
server and the mDia1 structure (e–f).20 The region corresponding
to the mDia1 IQGAP1-interacting DID subdomain (INF2 amino
acids 149 through 238) is colored yellow.13,21 New mutations
identified in the present study are shown in blue and mutations
identified in previous studies are shown in red.8,13 (e) Global front
view of the INF2 model. Residues N202 and A203 model to the
protein surface next to I152, a residue identified as important for
direct interaction with diaphanous autoregulatory domain.8,13
(f) Global rear view of the INF2 model. Residue E184 maps to
the surface of the protein and is adjacent to the previously
identified mutation in S186.
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differences observed in the three groups may be due to selection
bias. Genetic mutations known to cause nephrotic syndrome
and FSGS have previously been excluded in these families.14
The present study, in conjunction with the initial report by
Brown et al., and a recent study from France, suggest that
mutation in INF2 is the most common cause of AD FSGS.8,13
INF2 is a member of the formin family. Formin is one of
the three proteins that promote nucleation of actin, a rate-
limiting step in actin polymerization.9 The domain structure,
which is similar to the diaphanous formins, comprises
formin homology 1 and 2 domains (FH1 and FH2), DID,
and DAD.15 However, unlike the diaphanous formins, INF2 is
capable of enabling both actin polymerization and depoly-
merization.15 The depolymerization activity is regulated by
the interaction between the DID and the DAD domains.15,16
This step is inhibited by the binding of GTPase RhoA to the
N-terminal element DID. RhoA is able to facilitate this
because the binding site on DID partially overlaps with DAD;
in addition, RhoA facilitates auto-inhibition.12,17
We found three new mutations in this series, thereby
increasing the number of INF2mutations reported as a cause of
FSGS to 16.8,10,13 The changes reported in this study and
previous studies are conserved in evolution and are absent from
public single-nucleotide polymorphism databases, as well as
from the 1000 Genomes Project. Exon 4 contains all of the
disease-causing variants in the present study. When combined
with previous studies, 30 families with FSGS have been reported
to have INF2 mutations and 27/30 (90%) have mutations in
exon 4, whereas the remaining have mutations in exon 2 of
INF2. Exon 4 therefore appears to be a critical region for
mutations in this gene; in addition, it encodes the DID domain
of the protein that is responsible for auto-regulation of INF2
function. Most of the variants reported in this series have been
shown to cause mislocalization of INF2 in podocyte culture and
some of them also inhibit the interaction between INF2-DID
and mDias-DAD, suggesting that the changes are functionally
important for regulation of the actin cytoskeleton.8,17
There was wide variability in the clinical expression of
disease due to INF2 mutations. At the time of ascertainment,
7/33 individuals with INF2 mutations in this study were
known to be asymptomatic; three of these seven individuals
were in the age group of 45 to 73 years, whereas the other
four were less than 30 years of age. This is consistent with
incomplete penetrance that is often seen in AD disease. It
is possible that young subjects may develop FSGS with
advancing age. An alternative explanation may be that there
are yet-to-be identified genetic modifiers and environmental
factors that may explain this variable clinical expression.
The clinical implications of these findings reveal that there
may be a rationale for screening for mutations in exon 4 and
exon 2 of INF2 in presumed AD FSGS. We did not find
mutations in any of the other known FSGS genes (NPHS2,
ACTN4, TRPC6, CD2AP, and PLCE1) in about 92% of
the families studied, confirming that FSGS is genetically
heterogeneous and also suggesting the existence of other
disease-causing genes.18 With advances in genomics, such as
whole-exome and genome sequencing, other genetic causes
of FSGS will be identified and this will hopefully lead to a
better understanding of the disease pathogenesis and rapid
and noninvasive diagnosis of both the sporadic and familial
forms of the disease.
In conclusion, INF2 mutations are responsible for 16%
of all cases of AD FSGS in this series and, as reported, 90%
of the mutations are clustered in exon 4, a regulatory region
of the gene. Screening for mutations in exon 4 and exon 2 of
INF2 may represent a rapid, noninvasive, and cost-effective
method for the diagnosis of AD FSGS.
MATERIALS AND METHODS
Clinical data
Institutional Review Board approval was obtained from Duke
University Medical Center (Durham, NC). Methods of subject
recruitment have been previously reported.19 Inclusion criteria are
as follows: (1) diagnosis of biopsy-proven FSGS; (2) exclusion of
secondary causes of FSGS such as HIV infection, hepatitis, and
obesity; and (3) exclusion of mutations in known FSGS/nephrotic
syndrome genes. Clinical data obtained included a complete family
history, including other associated morbidities, age at onset of
disease, and age at ESKD, as well as history of kidney transplantation
and recurrence in the renal allograft. Albuminuria and serum
creatinine were measured using standard methods.
Mutational analysis
Genomic DNA was extracted from whole blood using the Qaigen/
Puregene kit (Qaigen, Hilden, Germany). Mutational analysis was
carried out by sequencing of both strands of all exons of INF2 using
exon-flanking primers; primer sequences are listed in Supplementary
Table S2 online. All sequences were analyzed with the Sequencher
software (Gene Codes, Ann Arbor, MI).
In silico prediction of impact of amino-acid substitution
All new non-synonymous variations were individually entered into
PolyPhen 2 software (http://genetics.bwh.harvard.edu/pph2/index.
shtml) to examine the predicted damaging effect of the amino-acid
substitution to the function of inverted formin 2 isoform 1 (Uniprot
ID: Q27J81). The HumVar-trained version was used, which is optimal
for Mendelian disorders as it distinguishes mutations with drastic
effects from all the remaining human variation, including abundant
mildly deleterious alleles. PolyPhen 2 calculates a Naive Bayes
posterior probability that any mutation is damaging and this is
represented with a score ranging from 0 to 1. A mutation was also
appraised qualitatively as benign, possibly damaging, or probably
damaging based on the model’s false-positive rate.11
Three-dimensional modeling of INF2 DID based on
structure of mDia1
The location and functional significance of new mutations in this
study were tested by designing a model of the human INF2 amino
acids 1–330 using the Phyre threading program.8,20 Models and
location of the mutated residues were predicted using PyMol (PyMOL
Molecular Graphics System, DeLano Scientific, San Carlos, CA).
Data analysis
The clinical data and frequency of mutations in INF2 were
compared between the single- and multigeneration families. All
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categorical data were compared by means of w2-test and continuous
variables by Student’s t-test if they were normally distributed,
and Kruskal–Wallis test for continuous data that are not normally
distributed.
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